Loading...
•
Jun 30, 2024
Fulcrum Therapeutics Q2 2024 Earnings Report
Announced financial results for the second quarter of 2024 and provided a business update.
Key Takeaways
Fulcrum Therapeutics reported financial results for Q2 2024, with a net income of $55.4 million primarily due to an $80.0 million upfront payment from Sanofi. The company is on track to report topline data for the Phase 3 REACH trial of losmapimod by the end of October 2024 and continues to advance its Phase 1b PIONEER trial of pociredir.
On track to report topline data for Phase 3 REACH trial of losmapimod in FSHD by the end of October 2024.
Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod.
234 patients had completed the Part A 48-week treatment phase of the REACH clinical trial as of June 30, 2024.
Continue to make progress in the Phase 1b trial evaluating pociredir in patients with sickle cell disease.
Forward Guidance
Based on its current operating plans, Fulcrum continues to expect that its cash, cash equivalents, and marketable securities as of June 30, 2024 will be sufficient to fund its operating requirements into 2027.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...